Radiocor News

Eli Lilly to buy Scorpion Therapeutics for up to 2.5 bln usd

(Il Sole 24 Ore Radiocor) - Milano, 13 gen - Eli Lilly said it had agreed to buy cancer therapy developer Scorpion Therapeutics in a deal worth up to 2.5 billion dollars in cash.

Lilly said it would acquire Scorpion's experimental oral therapy program STX-478 which is currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors.

Under the terms of the agreement, Lilly will acquire Scorpion and Scorpion shareholders could receive up to 2.5 billion in cash, Lilly said in a statement.

"Additionally, as part of the transaction, Scorpion will spin out a new entity to hold its employees and non-PI3K pipeline assets," it said.

Scorpion Therapeutics is a private biotechnology company.

developing small molecule precision oncology therapies.

(RADIOCOR) 13-01-25 19:30:44 (0558) 5 NNNN

 


The Exchange accepts no responsability for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.


You will be redirected in five seconds.